Forefront Analytics’s Poseida Therapeutics PSTX Stock Holding History
Bought
Maintained
Sold
Other funds holding PSTX
Forefront Analytics's PSTX Position: Q4 2024 in Review
Forefront Analytics sold out of Poseida Therapeutics (PSTX) in Q4 2024, closing a stake of 27,855 shares — an estimated $79.7K sold.
Forefront Analytics first reported a position in PSTX in Q3 2021 and held it in 13 quarters. The position peaked at $121K in Q1 2022. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.
- Forefront Analytics reported no remaining Poseida Therapeutics position as of Q4 2024 after selling out during the quarter.
- Forefront Analytics sold 27,855 Poseida Therapeutics shares in Q4 2024, an estimated $79.7K.
- Forefront Analytics first reported a position in Poseida Therapeutics in Q3 2021 and held it in 13 quarters.
- Forefront Analytics's Poseida Therapeutics position peaked at $121K in Q1 2022.
- 115 funds tracked by Wall St. Rank held Poseida Therapeutics as of Q4 2024.
Based on Forefront Analytics's 13F filing for Q4 2024, filed 14 Feb 2025.